{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-084159","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.211057+00:00","generated_at":"2026-05-31T14:43:21.669325+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theriva Biologics receives FDA Rare Pediatric Drug Designation for VCN-01 in retinoblastoma","bullets":["FDA grants Rare Pediatric Drug Designation for VCN-01, a stroma-degrading oncolytic adenovirus, to treat retinoblastoma.","Prior orphan drug designation for same indication; RPDD may provide a Priority Review Voucher upon BLA approval.","Holders of Series C Convertible Preferred Stock converted 135,431 shares into 888,072 common shares at $1.22 per share.","Positive Phase 1 results from investigator-sponsored trial of intravitreal VCN-01 in pediatric refractory retinoblastoma inform clinical pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-084159","json":"https://secwatch.observer/filing/0001104659-24-084159.json","markdown":"https://secwatch.observer/filing/0001104659-24-084159.md","text":"https://secwatch.observer/filing/0001104659-24-084159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924084159/0001104659-24-084159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924084159/tm2420486d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:43:21.669325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}